Immune cells from donors target deadly blood cancers in early trial
Disease control
Completed
This early-phase study tested a new treatment called WU-CART-007 in 28 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that had come back or not responded to standard therapy. The treatment uses donor immune cells engineered to find and attack cancer cel…
Phase: PHASE1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated May 01, 2026 15:24 UTC